262 related articles for article (PubMed ID: 24627483)
1. Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.
Vangala JR; Dudem S; Jain N; Kalivendi SV
J Biol Chem; 2014 May; 289(18):12612-22. PubMed ID: 24627483
[TBL] [Abstract][Full Text] [Related]
2. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
3. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
4. G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
Yang YM; Lee S; Nam CW; Ha JH; Jayaraman M; Dhanasekaran DN; Lee CH; Kwak MK; Kim SG
Carcinogenesis; 2010 Jul; 31(7):1230-7. PubMed ID: 20478922
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
Lü S; Chen Z; Yang J; Chen L; Gong S; Zhou H; Guo L; Wang J
Exp Hematol; 2008 Oct; 36(10):1278-84. PubMed ID: 18562081
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
Oerlemans R; Franke NE; Assaraf YG; Cloos J; van Zantwijk I; Berkers CR; Scheffer GL; Debipersad K; Vojtekova K; Lemos C; van der Heijden JW; Ylstra B; Peters GJ; Kaspers GL; Dijkmans BA; Scheper RJ; Jansen G
Blood; 2008 Sep; 112(6):2489-99. PubMed ID: 18565852
[TBL] [Abstract][Full Text] [Related]
7. Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Niewerth D; Jansen G; Riethoff LF; van Meerloo J; Kale AJ; Moore BS; Assaraf YG; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
Mol Pharmacol; 2014 Jul; 86(1):12-9. PubMed ID: 24737138
[TBL] [Abstract][Full Text] [Related]
8. Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation.
Jin S; Li B; Zhang B; Gao X; Jia X; Xu L; Chang S; Hu K; Wang G; Xu Z; Zhang T; Song D; Yang G; Wu X; Zhu H; Huang C; Lu Y; Shi J; Zhu W; Chen G
Acta Biochim Biophys Sin (Shanghai); 2023 Dec; 55(12):1884-1891. PubMed ID: 38009004
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
Li C; Zang Y; Sen M; Leeman-Neill RJ; Man DS; Grandis JR; Johnson DE
Mol Cancer Ther; 2009 Aug; 8(8):2211-20. PubMed ID: 19638453
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
Ri M; Iida S; Nakashima T; Miyazaki H; Mori F; Ito A; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Shiotsu Y; Ueda R
Leukemia; 2010 Aug; 24(8):1506-12. PubMed ID: 20555361
[TBL] [Abstract][Full Text] [Related]
11. Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells.
Singh V; Sharma V; Verma V; Pandey D; Yadav SK; Maikhuri JP; Gupta G
Eur J Nutr; 2015 Dec; 54(8):1255-67. PubMed ID: 25408199
[TBL] [Abstract][Full Text] [Related]
12. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
Zhang XD; Baladandayuthapani V; Lin H; Mulligan G; Li B; Esseltine DW; Qi L; Xu J; Hunziker W; Barlogie B; Usmani SZ; Zhang Q; Crowley J; Hoering A; Shah JJ; Weber DM; Manasanch EE; Thomas SK; Li BZ; Wang HH; Zhang J; Kuiatse I; Tang JL; Wang H; He J; Yang J; Milan E; Cenci S; Ma WC; Wang ZQ; Davis RE; Yang L; Orlowski RZ
Cancer Cell; 2016 May; 29(5):639-652. PubMed ID: 27132469
[TBL] [Abstract][Full Text] [Related]
13. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.
Lü S; Yang J; Chen Z; Gong S; Zhou H; Xu X; Wang J
Exp Hematol; 2009 Jul; 37(7):831-7. PubMed ID: 19426847
[TBL] [Abstract][Full Text] [Related]
14. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.
Baran-Marszak F; Boukhiar M; Harel S; Laguillier C; Roger C; Gressin R; Martin A; Fagard R; Varin-Blank N; Ajchenbaum-Cymbalista F; Ledoux D
Haematologica; 2010 Nov; 95(11):1865-72. PubMed ID: 20663948
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.
Kim JE; Jin DH; Lee WJ; Hur D; Wu TC; Kim D
Pharmacol Res; 2013 May; 71():23-33. PubMed ID: 23428347
[TBL] [Abstract][Full Text] [Related]
16. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
[No Abstract] [Full Text] [Related]
17. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
Lü S; Yang J; Song X; Gong S; Zhou H; Guo L; Song N; Bao X; Chen P; Wang J
J Pharmacol Exp Ther; 2008 Aug; 326(2):423-31. PubMed ID: 18502982
[TBL] [Abstract][Full Text] [Related]
18. Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Lichter DI; Danaee H; Pickard MD; Tayber O; Sintchak M; Shi H; Richardson PG; Cavenagh J; Bladé J; Façon T; Niesvizky R; Alsina M; Dalton W; Sonneveld P; Lonial S; van de Velde H; Ricci D; Esseltine DL; Trepicchio WL; Mulligan G; Anderson KC
Blood; 2012 Nov; 120(23):4513-6. PubMed ID: 23018640
[TBL] [Abstract][Full Text] [Related]
19. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
20. MiR-383 sensitizes osteosarcoma cells to bortezomib treatment via down-regulating PSMB5.
Wang H; Bai C; Dang X; Wang H
Mol Biol Rep; 2024 Jan; 51(1):170. PubMed ID: 38252234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]